<?xml version="1.0" encoding="UTF-8"?>
<p id="p0070">As the monomer of M
 <sup>pro</sup> is principally regarded as inactive, the dimerization interface offers an alternative target site for drug discovery.
 <xref rid="b0340" ref-type="bibr">68</xref>, 
 <xref rid="b0360" ref-type="bibr">72</xref> Although strong dimerization inhibitors are yet unavailable, the principle has been proven with the 
 <italic>N</italic>-terminal octapeptide of SARS-CoV M
 <sup>pro</sup>.
 <xref rid="b0445" ref-type="bibr">
  <sup>89</sup>
 </xref>
</p>
